Fluorescence in situ hybridization analyses of hematologic malignancies reveal frequent cytogenetically unrecognized 12p rearrangements

Leukemia
P AndreassonM Höglund

Abstract

Thirty-two hematologic malignancies--nine with cytogenetically identified 12p abnormalities and 23 with whole or partial losses of chromosome 12--were selected for fluorescence in situ hybridization (FISH) investigations of 12p. These analyses revealed structural 12p changes, such as translocations, deletions, insertions, inversions and amplification, in 20 cases. ETV6 rearrangements were detected in three acute leukemias. One acute undifferentiated leukemia had t(4;12)(q12;p13) as the sole anomaly. The second case, an acute myeloid leukemia (AML), displayed complex abnormalities involving, among others, chromosomes 9 and 12. The third case, also an AML, had an insertion of the distal part of ETV6 into chromosome arm 11q and into multiple ring chromosomes, which also contained chromosome 11 material, resulting in an amplification of a possible fusion gene. The fusion partners in these cases remain to be identified. Thirty-one additional breakpoints on 12p could be characterized in detail. The majority of these breaks were shown to result in interchromosomal rearrangements, possibly indicating the location of hitherto unrecognized genes of importance in the pathogenesis of hematologic malignancies. The FISH analyses disclosed te...Continue Reading

Citations

Aug 10, 1999·Luminescence : the Journal of Biological and Chemical Luminescence·P E Stanley, L J Kricka
Nov 7, 2000·Genes, Chromosomes & Cancer·S TosiL Kearney
May 30, 2002·Cancer Genetics and Cytogenetics·Michelle DolanBetsy Hirsch
Jul 20, 2002·Cancer Genetics and Cytogenetics·S FearsJ D Rowley
Oct 24, 2002·Cancer Genetics and Cytogenetics·Takashi SaitohTakashi Horie
Jan 22, 2004·Cancer Genetics and Cytogenetics·Jeanna WelbornPaula Walling
May 31, 2001·British Journal of Haematology·N MauritzsonP G Nilsson
Jul 31, 2001·Genes, Chromosomes & Cancer·C FonatschK Lechner
May 13, 2005·Mayo Clinic Proceedings·David P Steensma, Alan F List
Jan 12, 2012·British Journal of Haematology·Ceri H JonesDuncan M Baird
May 4, 2004·Cancer Genetics and Cytogenetics·Jeanna Welborn
Jul 23, 2004·The Journal of Molecular Diagnostics : JMD·Carmo MartinsIsabel Fonseca
Aug 24, 2017·São Paulo Medical Journal = Revista Paulista De Medicina·Maria Helena Faria OrnellasGilda Alves
Dec 6, 2005·Leukemia·G JuliussonUNKNOWN Swedish Adult Acute Leukemia Registry Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.